Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib combinations in stage IV NSCLC
NCT02079636Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of abemaciclib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose-Limiting Toxicities at 15 months. Started Mar 2014; status: completed.
02
Drugs
abemaciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02079636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079636.